<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475199</article-id><article-id pub-id-type="pmcid-ver">PMC12475199.1</article-id><article-id pub-id-type="pmcaid">12475199</article-id><article-id pub-id-type="pmcaiid">12475199</article-id><article-id pub-id-type="pmid">41006803</article-id><article-id pub-id-type="doi">10.1038/s41598-025-18693-5</article-id><article-id pub-id-type="publisher-id">18693</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Longitudinal changes in sleep quality, and their predictors in patients with multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yun</surname><given-names initials="H">Habin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seo</surname><given-names initials="D">Dayoung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yumin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jang</surname><given-names initials="IH">In-Hye</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choi</surname><given-names initials="L">Lynkyung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JH">Jin-Hee</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shin</surname><given-names initials="W">Wangyoung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="HM">Hye-Mi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jung</surname><given-names initials="HJ">Hee-Jae</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hyunjin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names initials="YM">Young-Min</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lee</surname><given-names initials="EJ">Eun-Jae</given-names></name><address><email>eunjae.lee@amc.seoul.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02c2f8975</institution-id><institution-id institution-id-type="GRID">grid.267370.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0533 4667</institution-id><institution>University of Ulsan College of Medicine, </institution></institution-wrap>Seoul, 05505 South Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s5q0090</institution-id><institution-id institution-id-type="GRID">grid.413967.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0842 2126</institution-id><institution>Department of Neurology, Asan Medical Center, University of Ulsan, </institution></institution-wrap>Seoul, 05505 South Korea </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33153</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_18693.pdf"/><abstract id="Abs1"><p id="Par2">Sleep disturbances are common among patients with multiple sclerosis (PwMS), yet their longitudinal course and clinical determinants remain unclear. Here, we aimed to examine sleep quality in PwMS, investigate its association with quality of life, and evaluate its trajectory and clinical predictors over time. Between September 2022 and September 2023, PwMS who had not experienced a recent clinical relapse (within &#8804;&#8201;2 months) were prospectively recruited. Sleep quality at baseline and after 6&#8211;12 months was measured using the Pittsburgh Sleep Quality Index (PSQI). Clinical factors associated with PSQI scores, and their longitudinal trajectories, were examined. A total of 118 patients with MS (median age, 46 years) were enrolled, with 54% identified as poor sleepers (PSQI&#8201;&gt;&#8201;5) at baseline and a comparable prevalence (53%) at follow-up. Poor sleep quality was associated independently with reduced quality of life. While PSQI scores remained generally stable over time in participants without clinical relapses during follow-up (<italic toggle="yes">n</italic>&#8201;=&#8201;114), 23 (20.2%) exhibited a marked deterioration in sleep quality (PSQI score increase&#8201;&#8805;&#8201;3). Baseline optic Functional Systems scores (baseline: &#946;&#8201;=&#8201;0.226 (95% confidence interval, 0.021, 1.115), follow-up: &#946;&#8201;=&#8201;0.233, (0.038, 1.311)) and depression (baseline: &#946;&#8201;=&#8201;0.261, (1.031, 5.822), follow-up: &#946;&#8201;=&#8201;0.215, (0.473, 5.935)) independently predicted both baseline and future PSQI scores. In conclusion, poor sleep quality is common and persistent in PwMS, with depression and the severity of optic dysfunction identified as key predictors. These findings emphasize the need for targeted sleep management in MS care.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-18693-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Multiple sclerosis</kwd><kwd>Sleep quality</kwd><kwd>PSQI</kwd><kwd>Neurologic disability</kwd><kwd>Longitudinal sleep quality</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Medical research</kwd><kwd>Neurology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), characterized by immune-mediated demyelination, axonal injury and loss, and subsequent neurodegeneration. Although it most commonly presents in young adults and follows a lifelong trajectory of relapses and progression, its underlying immunopathology, clinical manifestations, and prognosis are variable, resulting in a wide spectrum of neurological impairment<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">Sleep disturbance and poor sleep quality are common and often under-recognized manifestations in patients with MS (PwMS), affecting more than half of this population<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. These disturbances encompass a range of conditions, including restless leg syndrome (RLS), insomnia, and obstructive sleep apnea (OSA)<sup><xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref></sup>. Poor sleep quality is associated with a more severe disease course<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>&#160;and is linked closely to key MS symptoms such as fatigue<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>&#160;cognitive decline<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>&#160;and reduced health-related quality of life (HRQoL)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Despite its high prevalence and considerable impact, the long-term trajectory of sleep quality in PwMS, along with the key determinants and predictors of poor sleep, remains unclear.</p><p id="Par5">Given the wide spectrum of clinical trajectory and CNS involvement in MS, we hypothesized that sleep quality in PwMS would evolve over the disease course, and that these changes may be influenced by individual differences in brain function. To test these hypotheses, we designed a prospective study to examine longitudinal changes in sleep quality among PwMS, investigate its association with quality of life, and identify clinical variables that determine or predict sleep quality over time.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients and study design</title><p id="Par6">This study was a single-center, prospective, observational cohort investigation with a follow-up period of 6&#8211;12 months. Between September 2022 and September 2023, participants were recruited from the Neurology Outpatient Clinic at Asan Medical Center, South Korea. The inclusion criteria were as follows: age&#8201;&#8805;&#8201;18 years; a confirmed diagnosis of MS according to the McDonald Criteria (2017)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>; provision of informed consent prior to enrollment; and absence of an acute relapse within the 2 months prior to enrollment<sup><xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref></sup>. Cell-based assays were performed to detect antibodies specific for aquaporin-4 protein and myelin oligodendrocyte glycoprotein: all included participants tested negative<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Participants were excluded if they had an acute illness (e.g., myocardial infarction, unstable angina, new onset ischemic stroke or trauma) within 2 months of the study enrollment, or active cancer<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. The study complied with principles of the Declaration of Helsinki, and received approval from the Institutional Review Board/Ethics Committee of Asan Medical Center (No. 2018&#8201;&#8722;&#8201;0653). All participants provided written informed consent to inclusion in the study.</p></sec><sec id="Sec4"><title>Outcomes and measures</title><p id="Par7">Patients&#8217; sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a self-reported survey designed to evaluate sleep quality over the past month<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. The PSQI comprises 19 items, grouped into seven components: subjective sleep quality (C1), sleep onset latency (C2), sleep duration (C3), sleep efficiency (C4), sleep disturbance (C5), use of sleeping medication (C6), and daytime dysfunction (C7). Each component is scored on a scale from 0 to 3, with the total PSQI score ranging from 0 to 21. The PSQI has been validated extensively in various populations, including individuals with MS. This study used the Korean version of the PSQI (PSQI-K), which has been validated in the general Korean population<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Higher PSQI scores reflect poorer sleep quality, with a cutoff of &gt;&#8201;5 commonly used to define poor sleep<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. A significant worsening in sleep quality during follow-up was defined as an increase in the PSQI score by &#8805;&#8201;3 points<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par8">HRQoL was assessed using the EQ-5D-5&#160;L index, a self-administered survey that evaluates HRQoL across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Participants rated their health state on a five-level scale for each dimension, with higher levels indicating worse QoL. The EQ-5D-5&#160;L valuation Eq.&#160;2<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> was applied to calculate an overall HRQoL score, represented as the EQ-5D index. Lower EQ-5D index scores reflect poorer HRQoL.</p><p id="Par9">The Expanded Disability Status Scale (EDSS) was primarily assessed by MS specialist nurses and confirmed by neurologists, along with the Functional Systems (FS) Score, which evaluates symptoms or disabilities across eight neurological domains: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral (mental), and ambulation<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Follow-up EDSS scores obtained 6&#8211;12 months after baseline were used to assess disability progression. For patients with a baseline EDSS score of &#8804;&#8201;5.0, an increase of at least 1.0 point, in the absence of clinical relapse at the time of confirmation, was defined as unconfirmed disability progression (UDP). For those with a baseline EDSS score&#8201;&#8805;&#8201;5.5, UDP was defined as a 0.5-point increase without evidence of remission. Clinical variables, including demographic data (e.g., age and sex) and disease-related information (e.g., disease duration, comorbidities, and number of relapses), were collected. Depression was defined based on ICD-10 criteria (F32&#8211;F33)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and identified through corresponding diagnostic codes documented in the medical records.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par10">Demographic and clinical characteristics, as well as outcome variables, were summarized as percentages for categorical variables and as the median (range) for continuous variables. For longitudinal analysis, patients who experienced acute relapse during follow-up were excluded. Associations between global PSQI scores and other continuous clinical variables were examined using univariate linear regression analysis. Variables significantly associated with PSQI scores were included in multivariable regression models to identify independent predictors of both baseline and follow-up PSQI scores, adjusting for age, sex, disease duration, and baseline disability (EDSS scores). Statistical analyses were performed using IBM SPSS Statistics for Windows, version 27.0 (IBM Corp., Armonk, NY, USA). A p-value&#8201;&lt;&#8201;0.05 was considered statistically significant. Given the exploratory nature of this study, no adjustments were made for multiple comparisons.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p id="Par11">In total, 118 patients were initially enrolled and included in the cross-sectional analysis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The participants had a median age of 46 years (range: 20.0&#8211;70.0; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>), and 71% were female. The median disease duration was 5.5 years (range: 1.0&#8211;34.0). The median EDSS score was 2.0 (range: 0&#8210;7.5), and most (<italic toggle="yes">n</italic>&#8201;=&#8201;104, 96.6%) patients were receiving disease-modifying therapies, including 10 patients receiving high-efficacy treatments (8.5%). The majority of participants (<italic toggle="yes">n</italic>&#8201;=&#8201;113, 95.8%) were diagnosed with relapsing-remitting MS, four (3.4%) with secondary progressive MS, and one with primary progressive MS.</p><p id="Par12">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flow chart.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e362" position="float" orientation="portrait" xlink:href="41598_2025_18693_Fig1_HTML.jpg"/></fig>
</p><p id="Par13">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the participants, and their PSQI scores.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">All patients</th><th align="left" colspan="1" rowspan="1">Good sleepers<break/>(PSQI&#8201;&#8804;&#8201;5)</th><th align="left" colspan="1" rowspan="1">Poor sleepers<break/>(PSQI&#8201;&gt;&#8201;5)</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">p</italic>*</th></tr><tr><th align="left" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;118)</th><th align="left" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;54)</th><th align="left" colspan="1" rowspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;64)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, y (median (range))</td><td align="left" colspan="1" rowspan="1">46.0 (20.0&#8211;77.0)</td><td align="left" colspan="1" rowspan="1">43.0 (20.0&#8211;74.0)</td><td align="left" colspan="1" rowspan="1">47.0 (25.0&#8211;77.0)</td><td align="left" colspan="1" rowspan="1">0.297</td></tr><tr><td align="left" colspan="1" rowspan="1">Onset age, y (median (range))</td><td align="left" colspan="1" rowspan="1">38.0 (11.0&#8211;71.0)</td><td align="left" colspan="1" rowspan="1">31.0 (11.0&#8211;67.0)</td><td align="left" colspan="1" rowspan="1">38.0 (18.0&#8211;71.0)</td><td align="left" colspan="1" rowspan="1">0.392</td></tr><tr><td align="left" colspan="1" rowspan="1">Female (%)</td><td align="left" colspan="1" rowspan="1">84 (71.2)</td><td align="left" colspan="1" rowspan="1">40 (74.1)</td><td align="left" colspan="1" rowspan="1">44 (68.8)</td><td align="left" colspan="1" rowspan="1">0.530</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease duration, y (median (range))</td><td align="left" colspan="1" rowspan="1">5.5 (1.0&#8211;34.0)</td><td align="left" colspan="1" rowspan="1">6.0 (1.0&#8211;34.0)</td><td align="left" colspan="1" rowspan="1">11.0 (1.0&#8211;26.0)</td><td align="left" colspan="1" rowspan="1">0.322</td></tr><tr><td align="left" colspan="1" rowspan="1">Time since last attack, y (median (range))</td><td align="left" colspan="1" rowspan="1">4.4 (0.7&#8211;20.9)</td><td align="left" colspan="1" rowspan="1">4.4 (1.1&#8211;20.0)</td><td align="left" colspan="1" rowspan="1">4.7 (0.7&#8211;29.0)</td><td align="left" colspan="1" rowspan="1">0.631</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of relapses (median (range))</td><td align="left" colspan="1" rowspan="1">1.0 (1.0&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;8.0)</td><td align="left" colspan="1" rowspan="1">2.0 (1.0&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">0.010</td></tr><tr><td align="left" colspan="1" rowspan="1">Annualized Relapse Rate**</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Receiving DMT (n (%))</td><td align="left" colspan="1" rowspan="1">104 (96.6)</td><td align="left" colspan="1" rowspan="1">49 (90.7)</td><td align="left" colspan="1" rowspan="1">55 (85.9)</td><td align="left" colspan="1" rowspan="1">0.630</td></tr><tr><td align="left" colspan="1" rowspan="1">Receiving high-efficacy DMTs***</td><td align="left" colspan="1" rowspan="1">10 (8.5)</td><td align="left" colspan="1" rowspan="1">3 (5.6)</td><td align="left" colspan="1" rowspan="1">7 (10.9)</td><td align="left" colspan="1" rowspan="1">0.297</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline EDSS (median (range))</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;7.5)</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;7.5)</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;7.5)</td><td align="left" colspan="1" rowspan="1">0.149</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Optic Function</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;6.0)</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;6.0)</td><td align="left" colspan="1" rowspan="1">0.043</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Pyramidal Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;1.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">0.413</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Brainstem Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.717</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Cerebellar Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.423</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Sensory Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.247</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Bowel and Bladder function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.863</td></tr><tr><td align="left" colspan="1" rowspan="1">FS score: Cerebral Functions</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.025</td></tr><tr><td align="left" colspan="1" rowspan="1">Ambulation</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;11.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;10.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.&#8211;11.0)</td><td align="left" colspan="1" rowspan="1">0.644</td></tr><tr><td align="left" colspan="5" rowspan="1">Comorbidities</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Depression</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>11 (9.3)</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>2 (3.7)</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>9 (14.1)</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.054</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Systemic autoimmune disorders&#8224;</td><td align="left" colspan="1" rowspan="1">7 (5.9)</td><td align="left" colspan="1" rowspan="1">3 (5.6)</td><td align="left" colspan="1" rowspan="1">4 (6.3)</td><td align="left" colspan="1" rowspan="1">0.874</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">11 (9.3)</td><td align="left" colspan="1" rowspan="1">7 (13.0)</td><td align="left" colspan="1" rowspan="1">4 (6.3)</td><td align="left" colspan="1" rowspan="1">0.204</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">14 (11.9)</td><td align="left" colspan="1" rowspan="1">8 (14.8)</td><td align="left" colspan="1" rowspan="1">6 (9.4)</td><td align="left" colspan="1" rowspan="1">0.319</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">28 (23.7)</td><td align="left" colspan="1" rowspan="1">12 (22.2)</td><td align="left" colspan="1" rowspan="1">16 (25.0)</td><td align="left" colspan="1" rowspan="1">0.818</td></tr><tr><td align="left" colspan="1" rowspan="1">Migraine</td><td align="left" colspan="1" rowspan="1">10 (8.5)</td><td align="left" colspan="1" rowspan="1">4 (7.4)</td><td align="left" colspan="1" rowspan="1">6 (9.4)</td><td align="left" colspan="1" rowspan="1">0.702</td></tr><tr><td align="left" colspan="1" rowspan="1">Epilepsy</td><td align="left" colspan="1" rowspan="1">4 (3.4)</td><td align="left" colspan="1" rowspan="1">1 (3.7)</td><td align="left" colspan="1" rowspan="1">3 (4.7)</td><td align="left" colspan="1" rowspan="1">0.399</td></tr><tr><td align="left" colspan="1" rowspan="1">History of cerebrovascular stroke</td><td align="left" colspan="1" rowspan="1">4 (3.4)</td><td align="left" colspan="1" rowspan="1">2 (3.7)</td><td align="left" colspan="1" rowspan="1">2 (3.1)</td><td align="left" colspan="1" rowspan="1">0.863</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline PSQI score (median (range))</td><td align="left" colspan="1" rowspan="1">6.0 (1.0&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">4.0 (1.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">9.0 (6.0&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Notes: Values are presented as number (%) for sex and type of disease-modifying therapy, and as the median (range) for EDSS and all other measures. Higher PSQI scores indicate worse sleep quality.</p><p>p*: Good sleepers vs. Poor sleepers.</p><p>SD: Standard deviation; EDSS: Expanded Disability Status Scale; PSQI: Pittsburgh Sleep Quality Index; DMT: Disease-Modifying Therapy.</p><p>**ARR: annualized relapse rate = (total number of relapses)/(total people years). Calculated based on total number of attacks since disease onset and the sum of disease duration.</p><p><bold>***</bold>High-efficacy DMTs refer to Fingolimod, Alemtuzumab, and Cladribine.</p><p>&#8224;Systemic autoimmune conditions include autoimmune thyroid disorders (<italic toggle="yes">n</italic>&#8201;=&#8201;5), systemic lupus erythematosus (<italic toggle="yes">n</italic>&#8201;=&#8201;1), and ulcerative colitis (<italic toggle="yes">n</italic>&#8201;=&#8201;1).</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Sleep quality and its determinants</title><p id="Par14">At baseline, the median PSQI score was 6.0 (range 1.0&#8211;17.0), and 54.2% (<italic toggle="yes">n</italic>&#8201;=&#8201;64) of patients were classified as poor sleepers (PSQI&#8201;&gt;&#8201;5; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Age, sex, disease duration, EDSS score, and use of disease-modifying therapies did not differ significantly between the groups; however, poor sleepers had a higher number of relapses and worse functional system scores for the optic and cerebral domains than good sleepers. According to survey results, 22.4% (<italic toggle="yes">n</italic>&#8201;=&#8201;27) of patients were using sleep medications, among whom 26 were classified as poor sleepers at baseline.</p><p id="Par15">Univariable analysis of factors associated with baseline PSQI scores identified significant correlations between poorer sleep quality and higher baseline FS scores (worse function) in both the optic and cerebral domains, and the presence of depression (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Multivariable analysis identified FS scores in the optic domain and the presence of depression as being associated with sleep quality. Specifically, each one-point increase in the optic FS score was associated with a 0.226-point increase in baseline PSQI scores (<italic toggle="yes">p</italic>&#8201;=&#8201;0.042), while the presence of depression corresponded to a 0.261-point increase (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005). Although a one-point increase in the cerebral FS score was correlated to a 0.164-point increase, the results were statistically insignificant (<italic toggle="yes">p</italic>&#8201;=&#8201;0.085).</p><p id="Par16">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Correlates (predictors) of baseline PSQI scores.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">Baseline PSQI</th></tr><tr><th align="left" colspan="1" rowspan="1">Univariate Analysis</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">Multivariable analysis</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">0.085 (&#8722;0.026, 0.070)</td><td char="." align="char" colspan="1" rowspan="1">0.365</td><td align="left" colspan="1" rowspan="1">0.051 (&#8722;0.039, 0.065)</td><td char="." align="char" colspan="1" rowspan="1">0.549</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (female)</td><td align="left" colspan="1" rowspan="1">&#8722;0.063 (&#8722;0.988, 2.001)</td><td char="." align="char" colspan="1" rowspan="1">0.484</td><td align="left" colspan="1" rowspan="1">0.101 (&#8722;0.677, 2.308)</td><td char="." align="char" colspan="1" rowspan="1">0.563</td></tr><tr><td align="left" colspan="1" rowspan="1">Onset age</td><td align="left" colspan="1" rowspan="1">0.073 (&#8722;0.029, 0.066)</td><td char="." align="char" colspan="1" rowspan="1">0.436</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Disease duration (yrs)</td><td align="left" colspan="1" rowspan="1">0.021 (&#8722;0.083, 0.105)</td><td char="." align="char" colspan="1" rowspan="1">0.821</td><td align="left" colspan="1" rowspan="1">&#8722;0.054 (&#8722;0.139, 0.083)</td><td char="." align="char" colspan="1" rowspan="1">0.505</td></tr><tr><td align="left" colspan="1" rowspan="1">Time since last attack (yrs)</td><td align="left" colspan="1" rowspan="1">0.047 (&#8722;0.118, 0.185)</td><td char="." align="char" colspan="1" rowspan="1">0.664</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of past attacks</td><td align="left" colspan="1" rowspan="1">0.103 (&#8722;0.133, 0.472)</td><td char="." align="char" colspan="1" rowspan="1">0.270</td><td align="left" colspan="1" rowspan="1">0.114 (&#8722;0.165, 0.543)</td><td char="." align="char" colspan="1" rowspan="1">0.178</td></tr><tr><td align="left" colspan="1" rowspan="1">baseline EDSS</td><td align="left" colspan="1" rowspan="1">0.065 (&#8722;0.239, 0.490)</td><td char="." align="char" colspan="1" rowspan="1">0.496</td><td align="left" colspan="1" rowspan="1">&#8722;0.159 (&#8722;0.772, 0.159)</td><td char="." align="char" colspan="1" rowspan="1">0.173</td></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Optic Function</td><td align="left" colspan="1" rowspan="1">0.230 (0.126, 1.032)</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td align="left" colspan="1" rowspan="1">0.226 (0.021, 1.115)</td><td char="." align="char" colspan="1" rowspan="1">0.042</td></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Pyramidal Function</td><td align="left" colspan="1" rowspan="1">&#8722;0.023 (&#8722;1.914, 1.492)</td><td char="." align="char" colspan="1" rowspan="1">0.806</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Brainstem Function</td><td align="left" colspan="1" rowspan="1">&#8722;0.096 (&#8722;1174, 0.376)</td><td char="." align="char" colspan="1" rowspan="1">0.310</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Cerebellar Function</td><td align="left" colspan="1" rowspan="1">&#8722;0.01 (&#8722;0.703, 0.631)</td><td char="." align="char" colspan="1" rowspan="1">0.915</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Sensory Function</td><td align="left" colspan="1" rowspan="1">0.019 (&#8722;0.553, 0.675)</td><td char="." align="char" colspan="1" rowspan="1">0.845</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Bowel and Bladder function</td><td align="left" colspan="1" rowspan="1">&#8722;0.054 (&#8722;1.384, 0.765)</td><td char="." align="char" colspan="1" rowspan="1">0.569</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Cerebral Functions</td><td align="left" colspan="1" rowspan="1">0.201 (0.114, 2.269)</td><td char="." align="char" colspan="1" rowspan="1">0.030</td><td align="left" colspan="1" rowspan="1">0.164 (&#8722;0.132, 2.028)</td><td char="." align="char" colspan="1" rowspan="1">0.085</td></tr><tr><td align="left" colspan="1" rowspan="1">Ambulation</td><td align="left" colspan="1" rowspan="1">&#8722;0.001 (&#8722;0.274, 0.273)</td><td char="." align="char" colspan="1" rowspan="1">0.996</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Depression</td><td align="left" colspan="1" rowspan="1">0.281 (1.317, 5.757)</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td align="left" colspan="1" rowspan="1">0.261 (1.031, 5.822)</td><td char="." align="char" colspan="1" rowspan="1">0.005</td></tr></tbody></table><table-wrap-foot><p>Notes: Higher PSQI scores indicate worse sleep quality.</p><p>Higher EDSS and FS scores indicate worse neurologic disability and function, respectively.</p><p>PSQI: Pittsburgh Sleep Quality Index; CI: Confidence interval; EDSS: Expanded Disability Status Scale; FSS: Functional Systems Score; &#946;: Standardized beta coefficients.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Sleep and quality of life</title><p id="Par17">To assess the importance of sleep quality for PwMS, we examined its impact on QoL. Poor sleepers had significantly lower overall scores (median: 0.5 vs. 0.6 for good sleepers; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), where lower values reflect worse QoL (Supplementary Table 1). The difference was particularly notable in the mobility (median: 2.0 vs. 1.0; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003) and pain/discomfort (median: 3.0 vs. 2.0; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) domains, for which higher scores indicate greater impairment.</p><p id="Par18">Multivariable analyses supported these findings, indicating that both poor sleep status and worse sleep quality, as reflected by higher baseline PSQI scores, were associated independently with reduced QoL (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). After controlling for age, sex, disease duration, number of previous relapses, and baseline EDSS scores, poor sleep quality (PSQI&#8201;&gt;&#8201;5) remained a significant independent predictor of lower EQ-5D-5&#160;L scores (&#946; = &#8722;0.199; <italic toggle="yes">p</italic>&#8201;=&#8201;0.032; Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, MODEL 1). Similarly, higher PSQI scores were significantly associated with worse QoL (&#946; = &#8722;0.286; <italic toggle="yes">p</italic>&#8201;=&#8201;0.001; Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, MODEL 2).</p><p id="Par19">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Models for quality of life.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="1" rowspan="1">Univariate analysis</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (yrs)</td><td align="left" colspan="1" rowspan="1">&#8722;0.300 (&#8722;0.005, &#8722;0.001)</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">&#8722;0.213 (&#8722;0.004, 0.000)</td><td align="left" colspan="1" rowspan="1">0.034</td><td align="left" colspan="1" rowspan="1">&#8722;0.203 (&#8722;0.004, 0.000)</td><td align="left" colspan="1" rowspan="1">0.037</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (female)</td><td align="left" colspan="1" rowspan="1">0.178 (&#8722;0.001, 0.117)</td><td align="left" colspan="1" rowspan="1">0.056</td><td align="left" colspan="1" rowspan="1">0.114 (&#8722;0.020, 0.094)</td><td align="left" colspan="1" rowspan="1">0.205</td><td align="left" colspan="1" rowspan="1">0.115 (&#8722;0.018, 0.092)</td><td align="left" colspan="1" rowspan="1">0.189</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease duration (yrs)</td><td align="left" colspan="1" rowspan="1">&#8722;0.164 (&#8722;0.006, 0.000)</td><td align="left" colspan="1" rowspan="1">0.078</td><td align="left" colspan="1" rowspan="1">0.020 (&#8722;0.004, 0.005)</td><td align="left" colspan="1" rowspan="1">0.849</td><td align="left" colspan="1" rowspan="1">0.025 (&#8722;0.004, 0.005)</td><td align="left" colspan="1" rowspan="1">0.812</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of attacks</td><td align="left" colspan="1" rowspan="1">&#8722;0.197 (&#8722;0.025, &#8722;0.001)</td><td align="left" colspan="1" rowspan="1">0.034</td><td align="left" colspan="1" rowspan="1">&#8722;0.161 (&#8722;0.024, 0.003)</td><td align="left" colspan="1" rowspan="1">0.134</td><td align="left" colspan="1" rowspan="1">&#8722;0.176 (&#8722;0.024, 0.002)</td><td align="left" colspan="1" rowspan="1">0.087</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline EDSS</td><td align="left" colspan="1" rowspan="1">&#8722;0.214 (&#8722;0.031, &#8722;0.002)</td><td align="left" colspan="1" rowspan="1">0.023</td><td align="left" colspan="1" rowspan="1">&#8722;0.112 (&#8722;0.024, 0.007)</td><td align="left" colspan="1" rowspan="1">0.262</td><td align="left" colspan="1" rowspan="1">&#8722;0.123 (&#8722;0.024, 0.005)</td><td align="left" colspan="1" rowspan="1">0.201</td></tr><tr><td align="left" colspan="7" rowspan="1">Sleep variables</td></tr><tr><td align="left" colspan="1" rowspan="1">Poor sleepers at baseline</td><td align="left" colspan="1" rowspan="1">&#8722;0.273 (&#8722;0.134, &#8722;0.028)</td><td align="left" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">&#8722;0.199 (&#8722;0.111, &#8722;0.005)</td><td align="left" colspan="1" rowspan="1">0.032</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Baseline PSQI score</td><td align="left" colspan="1" rowspan="1">&#8722;0.349 (&#8722;0.021, &#8722;0.007)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8722;0.286 (&#8722;0.018, &#8722;0.005)</td><td align="left" colspan="1" rowspan="1">0.001</td></tr></tbody></table><table-wrap-foot><p>Notes: Higher PSQI scores indicate worse sleep quality. Higher EDSS and FS scores indicate worse neurologic disability.</p><p>PSQI: Pittsburgh Sleep Quality Index; CI: Confidence interval; EDSS: Expanded Disability Status Scale; FSS: Functional Systems Score; &#946;: Standardized beta coefficient.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Longitudinal sleep quality trajectories and associated factors</title><p id="Par20">During the follow-up period (median: 9.2 months; range: 6.0&#8211;12.5 months), two patients were lost to follow-up and two experienced acute relapse, leaving 114 patients eligible for longitudinal analysis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Among these, six patients (5.3%) exhibited UDP.</p><p id="Par21">At the population level, sleep quality remained largely stable over time. There was no significant change in PSQI scores from baseline (median PSQI scores: 6.0 vs. 6.0; <italic toggle="yes">p</italic>&#8201;=&#8201;0.437; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), and 53.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;61) of patients continued to meet the criteria for poor sleep at follow-up.</p><p id="Par22">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Longitudinal course of sleep quality, and changes in individuals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1212" position="float" orientation="portrait" xlink:href="41598_2025_18693_Fig2_HTML.jpg"/></fig>
</p><p id="Par23">The box and whisker graph (orange bars) shows the distribution of baseline and follow-up PSQI scores in our cohort, and the gray paired line graph visualizes individual shifts in PSQI scores throughout the study period. According to paired t-test results, sleep quality remained relatively stable (unchanged) at the population level (paired t-test: p-value&#8201;=&#8201;0.489).</p><p id="Par24">When exploring clinical factors associated with sleep quality, univariable analysis revealed that baseline cerebral FS scores, optic FS scores, and the presence of depression were significantly associated with follow-up PSQI scores, mirroring baseline findings. In multivariable analysis, optic FS scores and depression remained significant independent predictors of follow-up sleep quality (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>), highlighting the stability of clinical correlates over time. There were no significant differences in PSQI scores between patients with and without UDP, and only one UDP case exhibited a substantial decline in sleep quality (Supplementary Table 2).</p><p id="Par25">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Predictors of future PSQI scores.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">Follow-up PSQI</th></tr><tr><th align="left" colspan="1" rowspan="1">Univariate Analysis</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">Multivariable analysis</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th><th align="left" colspan="1" rowspan="1">&#946; (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">0.078 (&#8722;0.032, 0.079)</td><td char="." align="char" colspan="1" rowspan="1">0.408</td><td align="left" colspan="1" rowspan="1">0.026 (&#8722;0.051, 0.066)</td><td char="." align="char" colspan="1" rowspan="1">0.798</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (female)</td><td align="left" colspan="1" rowspan="1">&#8722;0.156 (&#8722;0.252, 3.199)</td><td char="." align="char" colspan="1" rowspan="1">0.094</td><td align="left" colspan="1" rowspan="1">&#8722;0.177 (&#8722;3.311, 0.041)</td><td char="." align="char" colspan="1" rowspan="1">0.056</td></tr><tr><td align="left" colspan="1" rowspan="1">Onset age</td><td align="left" colspan="1" rowspan="1">0.013 (&#8722;0.051, 0.059)</td><td char="." align="char" colspan="1" rowspan="1">0.894</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Disease duration (yrs)</td><td align="left" colspan="1" rowspan="1">0.132 (&#8722;0.031, 0.187)</td><td char="." align="char" colspan="1" rowspan="1">0.157</td><td align="left" colspan="1" rowspan="1">0.036 (&#8722;0.102, 0.144)</td><td char="." align="char" colspan="1" rowspan="1">0.335</td></tr><tr><td align="left" colspan="1" rowspan="1">Time since last attack (yrs)</td><td align="left" colspan="1" rowspan="1">0.111 (&#8722;0.087, 0.276)</td><td char="." align="char" colspan="1" rowspan="1">0.305</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of past attacks</td><td align="left" colspan="1" rowspan="1">0.109 (&#8722;0.145, 0.560)</td><td char="." align="char" colspan="1" rowspan="1">0.246</td><td align="left" colspan="1" rowspan="1">0.095 (&#8722;0.211, 0.572)</td><td char="." align="char" colspan="1" rowspan="1">0.363</td></tr><tr><td align="left" colspan="1" rowspan="1">baseline EDSS</td><td align="left" colspan="1" rowspan="1">0.163 (&#8722;0.051, 0.793)</td><td char="." align="char" colspan="1" rowspan="1">0.084</td><td align="left" colspan="1" rowspan="1">&#8722;0.090 (&#8722;0.728, 0.325)</td><td char="." align="char" colspan="1" rowspan="1">0.450</td></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Optic Function</td><td align="left" colspan="1" rowspan="1">0.236 (0.164, 1.227)</td><td char="." align="char" colspan="1" rowspan="1">0.011</td><td align="left" colspan="1" rowspan="1">0.233 (0.038, 1.311)</td><td char="." align="char" colspan="1" rowspan="1">0.038</td></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Pyramidal Function</td><td align="left" colspan="1" rowspan="1">0.072 (&#8722;1.230, 2.754)</td><td char="." align="char" colspan="1" rowspan="1">0.450</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Brainstem Function</td><td align="left" colspan="1" rowspan="1">0.01 (&#8722;0.863, 0.963)</td><td char="." align="char" colspan="1" rowspan="1">0.914</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Cerebellar Function</td><td align="left" colspan="1" rowspan="1">0.086 (&#8722;0.423, 1.136)</td><td char="." align="char" colspan="1" rowspan="1">0.367</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Sensory Function</td><td align="left" colspan="1" rowspan="1">0.043 (&#8722;0.555, 0.883)</td><td char="." align="char" colspan="1" rowspan="1">0.652</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">FSS: Bowel and Bladder function</td><td align="left" colspan="1" rowspan="1">&#8722;0.096 (&#8722;1.898, 0.614)</td><td char="." align="char" colspan="1" rowspan="1">0.313</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">FSS: Cerebral Functions</italic>
</td><td align="left" colspan="1" rowspan="1">0.232 (0.349, 2.860)</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td align="left" colspan="1" rowspan="1">0.170 (&#8722;0.092, 2.401)</td><td char="." align="char" colspan="1" rowspan="1">0.069</td></tr><tr><td align="left" colspan="1" rowspan="1">Ambulation</td><td align="left" colspan="1" rowspan="1">0.092 (&#8722;0.163, 0.476)</td><td char="." align="char" colspan="1" rowspan="1">0.334</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Depression</td><td align="left" colspan="1" rowspan="1">0.279 (1.414, 6.551)</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">0.215 (0.473, 5.935)</td><td char="." align="char" colspan="1" rowspan="1">0.022</td></tr></tbody></table><table-wrap-foot><p>Notes: Higher PSQI scores indicate worse sleep quality.</p><p>Higher EDSS and FS scores indicate worse neurologic disability and function, respectively.</p><p>PSQI: Pittsburgh Sleep Quality Index; CI: Confidence interval; EDSS: Expanded Disability Status Scale; FSS: Functional Systems Score; &#946;: Standardized beta coefficient.</p></table-wrap-foot></table-wrap>
</p><p id="Par26">Despite this overall stability, 23 patients (20.2%) experienced a clinically meaningful deterioration in sleep quality. This subgroup showed numerically higher cerebral and optic FS scores than the rest of the cohort, although the differences were not statistically significant (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>); however, multivariable logistic regression identified no independent predictors of sleep quality deterioration (Supplementary Table 3).</p><p id="Par27">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Comparative characteristics of those with significantly worsened sleep quality (<italic toggle="yes">n</italic>&#8201;=&#8201;23).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Significantly worsened<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;23)</th><th align="left" colspan="1" rowspan="1">Not worsened<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;91)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (yrs, median(range))</td><td align="left" colspan="1" rowspan="1">48.0 (26.0&#8211;67.0)</td><td align="left" colspan="1" rowspan="1">45.0 (20.0&#8211;77.0)</td><td align="left" colspan="1" rowspan="1">0.601</td></tr><tr><td align="left" colspan="1" rowspan="1">Female (%)</td><td align="left" colspan="1" rowspan="1">14 (60.9%)</td><td align="left" colspan="1" rowspan="1">66 (72.5%)</td><td align="left" colspan="1" rowspan="1">0.275</td></tr><tr><td align="left" colspan="1" rowspan="1">Onset age (yrs, median(range))</td><td align="left" colspan="1" rowspan="1">37.0 (15.0&#8211;56.0)</td><td align="left" colspan="1" rowspan="1">34.0 (11.0&#8211;71.0)</td><td align="left" colspan="1" rowspan="1">0.641</td></tr><tr><td align="left" colspan="1" rowspan="1">Disease duration (yrs, median(range))</td><td align="left" colspan="1" rowspan="1">11.5 (1.0&#8211;23.0)</td><td align="left" colspan="1" rowspan="1">8.0 (1.0&#8211;34.0)</td><td align="left" colspan="1" rowspan="1">0.727</td></tr><tr><td align="left" colspan="1" rowspan="1">Total number of attacks (median(range))</td><td align="left" colspan="1" rowspan="1">2.0 (1.0&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">2.0 (1.0&#8211;8.0)</td><td align="left" colspan="1" rowspan="1">0.424</td></tr><tr><td align="left" colspan="1" rowspan="1">Time since last attack (yrs, median(range))</td><td align="left" colspan="1" rowspan="1">6.3 (0.7&#8211;13.5)</td><td align="left" colspan="1" rowspan="1">4.3 (1.1&#8211;20.6)</td><td align="left" colspan="1" rowspan="1">0.682</td></tr><tr><td align="left" colspan="1" rowspan="1">Baseline EDSS (median(range))</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;6.5)</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;7.5)</td><td align="left" colspan="1" rowspan="1">0.287</td></tr><tr><td align="left" colspan="4" rowspan="1">FSS scores</td></tr><tr><td align="left" colspan="1" rowspan="1">Optic Function</td><td align="left" colspan="1" rowspan="1">2.0 (0.0&#8211;6.0)</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;6.0)</td><td align="left" colspan="1" rowspan="1">0.094</td></tr><tr><td align="left" colspan="1" rowspan="1">Pyramidal Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;1.0)</td><td align="left" colspan="1" rowspan="1">0.971</td></tr><tr><td align="left" colspan="1" rowspan="1">Brainstem Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.404</td></tr><tr><td align="left" colspan="1" rowspan="1">Cerebellar Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.294</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensory Function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.732</td></tr><tr><td align="left" colspan="1" rowspan="1">Bowel and Bladder function</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;3.0)</td><td align="left" colspan="1" rowspan="1">0.754</td></tr><tr><td align="left" colspan="1" rowspan="1">Cerebral Functions</td><td align="left" colspan="1" rowspan="1">1.0 (0.0&#8211;2.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;4.0)</td><td align="left" colspan="1" rowspan="1">0.067</td></tr><tr><td align="left" colspan="1" rowspan="1">Ambulation</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;8.0)</td><td align="left" colspan="1" rowspan="1">0.0 (0.0&#8211;11.0)</td><td align="left" colspan="1" rowspan="1">0.465</td></tr><tr><td align="left" colspan="4" rowspan="1">Comorbidities</td></tr><tr><td align="left" colspan="1" rowspan="1">Depression</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td><td align="left" colspan="1" rowspan="1">9 (9.9)</td><td align="left" colspan="1" rowspan="1">0.862</td></tr><tr><td align="left" colspan="1" rowspan="1">Systemic autoimmune disorders&#8224;</td><td align="left" colspan="1" rowspan="1">3 (13.0)</td><td align="left" colspan="1" rowspan="1">4 (4.4)</td><td align="left" colspan="1" rowspan="1">0.134</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">11 (12.1)</td><td align="left" colspan="1" rowspan="1">0.132</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes Mellitus</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td><td align="left" colspan="1" rowspan="1">12 (13.2)</td><td align="left" colspan="1" rowspan="1">0.590</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">7 (30.4)</td><td align="left" colspan="1" rowspan="1">21 (23.1)</td><td align="left" colspan="1" rowspan="1">0.410</td></tr><tr><td align="left" colspan="1" rowspan="1">Migraine</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td><td align="left" colspan="1" rowspan="1">7 (7.7)</td><td align="left" colspan="1" rowspan="1">0.873</td></tr><tr><td align="left" colspan="1" rowspan="1">Epilepsy</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td><td align="left" colspan="1" rowspan="1">2 (2.2)</td><td align="left" colspan="1" rowspan="1">0.130</td></tr><tr><td align="left" colspan="1" rowspan="1">History of cerebrovascular stroke</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td><td align="left" colspan="1" rowspan="1">2 (2.2)</td><td align="left" colspan="1" rowspan="1">0.130</td></tr></tbody></table><table-wrap-foot><p>Notes: Higher PSQI scores indicate worse sleep quality. Higher EDSS and FS scores indicate worse neurologic disability and function, respectively.</p><p>PSQI: Pittsburgh Sleep Quality Index; CI: Confidence interval; EDSS: Expanded Disability Status Scale; FSS: Functional Systems Score; &#946;: Pearson&#8217;s coefficient.</p></table-wrap-foot></table-wrap>
</p><p id="Par28">Notably, two patients who experienced relapses, but were excluded from the longitudinal analyses, also showed sleep quality deterioration. One patient with transverse myelitis (EDSS: 5.5 &#8594; 6.5) exhibited a marked increase in the PSQI score (11 &#8594; 17), while the other with optic neuritis (EDSS: 0 &#8594; 1.5) showed only a slight increase (4 &#8594; 5).</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par29">This prospective longitudinal study explored sleep quality and its longitudinal dynamics in PwMS. Poor sleep quality, which is significantly associated with QoL, was observed in over half of participants both at baseline and at follow-up. Although sleep quality remained largely stable at the population-level over time, there was a notable deterioration in 20.2% of patients. Baseline neurological function and the psychiatric comorbidities were found to be associated with sleep quality, with baseline optic FS scores and the presence of depression showing independent correlation with both baseline and follow-up PSQI scores.</p><p id="Par30">Our findings confirm the high prevalence of poor sleep quality in PwMS, with 54% classified as poor sleepers (PSQI&#8201;&gt;&#8201;5) at baseline; these findings align with several studies reporting poor sleep in over half of PwMS<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The mean PSQI score in our cohort was 7.0 (SD 3.7), indicating more severe sleep quality impairment than in both the Korean general population (mean 5.6, SD 3.2)<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and patients with rheumatoid arthritis (mean 5.6, SD 4.2)<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par31">Sleep quality was identified as an independent contributor to QoL, emphasizing its clinical significance. Among QoL domains, the &#8220;Pain and Discomfort&#8221; dimension of the EQ-5D-5&#160;L showed the strongest correlation with PSQI scores, supporting a reciprocal relationship: Poor sleep heightens pain perception<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref></sup>while chronic pain in turn disrupts sleep architecture<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. The link between poor sleep quality and reduced QoL in our cohort aligns with prior evidence that associates poor sleep with increased fatigue<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>cognitive impairment<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>and overall functional decline in MS.</p><p id="Par32">Longitudinally, over a median follow-up period of 9.2 months (range: 6.0&#8211;12.5 months), sleep quality remained relatively stable at the population level, with the proportion of poor sleepers showing minimal change (54.3% at baseline vs. 53.4% at follow-up). This aligns with the BETASLEEP study<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>a 2-year prospective investigation of German PwMS treated with interferon beta-1&#946;. This study reported stable mean PSQI scores across time points (baseline (mean, SD): 6.8 (4.0); year 1&#8201;=&#8201;6.0 (3.2); year 2&#8201;=&#8201;6.3 (3.6)) and similar proportions of poor sleepers over the follow-up period (57.1% at baseline and year 1, and 53.6% at year 2). Given the significant impact of poor sleep on the QoL of PwMS, these findings underscore the importance of early identification and long-term management of sleep disturbances in this population.</p><p id="Par33">Optic dysfunction emerged as an independent risk factor for poor sleep at both baseline and follow-up. Optic neuritis, a common manifestation of MS, leads to demyelination of the optic nerve and impaired light transmission<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Given that circadian rhythms are regulated by photic input from the retina to the suprachiasmatic nucleus<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>damage to the visual pathway may disrupt circadian rhythm entrainment, thereby contributing to generally reduced sleep quality<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. This mechanism may explain the association between optic dysfunction and elevated PSQI scores observed in our cohort. Although this finding emphasizes the role of insomnia-like symptoms, it does not diminish the potential contribution of other sleep disorders such as obstructive sleep apnea (OSA) or restless legs syndrome (RLS). It should be noted that the PSQI is particularly sensitive to symptoms typical of insomnia, such as prolonged sleep latency and poor sleep efficiency, while being less effective at capturing disturbances more specific to OSA or RLS, such as breathing pauses or limb movements<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Given that various sleep disorders are prevalent among PwMS, and we did not specifically assess their presence, the observed poor sleep quality should not be attributed solely to insomnia-like symptoms.</p><p id="Par34">Depression was identified as another independent risk factor for poor sleep quality in PwMS, consistent with existing literature highlighting the strong association between mental health and sleep disturbances. Depression is highly prevalent in MS and may contribute to sleep disruption through several mechanisms, including neuroinflammation, hypothalamic&#8211;pituitary&#8211;adrenal (HPA) axis dysregulation, and altered monoaminergic signaling<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Clinically, depressive symptoms such as difficulty initiating or maintaining sleep and non-restorative sleep are well reflected in elevated PSQI scores<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> Furthermore, depression often coexists with fatigue, which may amplify perceived sleep disturbances and further deteriorate sleep quality<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref></sup>. Our findings suggest that the adverse impact of depression on sleep is not transient but may persist throughout the disease course, reinforcing the need for routine screening and appropriate management of psychiatric symptoms in PwMS to improve both mental health and sleep-related outcomes.</p><p id="Par35">While cerebral FS scores initially appeared to correlate with sleep quality, this association did not remain significant after adjusting for other covariates in multivariate analyses. Cerebral dysfunction, including cognitive impairment and mood disturbances, is linked closely to sleep disruption and may interact bidirectionally, with poor sleep quality potentially exacerbating these symptoms<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Notably, patients who experienced a clinically meaningful decline in sleep quality over time had higher baseline cerebral and optic FS scores, although these factors were not identified as independent predictors in the multivariable regression. Future larger studies are warranted to confirm these associations.</p><p id="Par36">This study has several strengths. Unlike many cross-sectional investigations, we collected longitudinal data, capturing changes in sleep quality at the individual level over time. Another key strength is inclusion of detailed neurological evaluations, combining FS scores with EDSS. While the EDSS is used widely, its emphasis on ambulation and visual function may underrepresent cognitive and affective aspects of disease burden<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. By integrating FS scores, our approach offers a more comprehensive assessment of neurological status and its association with sleep quality. Importantly, our findings suggest that baseline optic dysfunction (and to some degree, cerebral dysfunction) may serve as early indicators of future sleep quality. Identifying such predictors is clinically relevant, as sleep is modifiable, and linked closely to QoL and disease progression in PwMS.</p><p id="Par37">Several limitations should be acknowledged. First, this single-center study involved a relatively small sample size, which May limit the generalizability of the findings. Second, the follow-up period of 6&#8211;12 months provides only a short observational window, potentially limiting detection of long-term sleep trajectories. Our method of assessing sleep quality, the PSQI questionnaire, has several important considerations. Although the PSQI is widely used to evaluate overall subjective sleep quality, elevated scores may arise from a variety of underlying factors, including insomnia symptoms, circadian rhythm disruption, nocturnal pain, or unrecognized comorbid conditions such as OSA or RLS. The PSQI does not differentiate between these contributing factors and is primarily validated for identifying insomnia-like symptoms. As such, it may not accurately capture disturbances specific to disorders like OSA<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Since we did not perform polysomonography, assess specific types of sleep disturbances, or administer disorder-specific screening tools (e.g., STOP-Bang for OSA<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>&#160;RLS-DI for RLS<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>), elevated PSQI scores in our cohort should be interpreted as a general reflection of poor subjective sleep quality rather than as indicative of a particular sleep disorder. This represents a limitation of the present analysis and highlights the need for more comprehensive sleep assessments in future studies. Regarding our data on depression, our analysis of psychiatric disorders (with the use of diagnostic codes) may also have underestimated the presence of depressive symptoms. Use of psychiatric surveys such as the Beck&#8217;s Depression Inventory (BDI)&#160;should be included in future longitudinal studies to further elucidate long term associations between sleep and depressive symptoms. Additionally, the impact of disease progression on sleep was not directly assessed, particularly in terms of subclinical disease activity, including chronic lesion burden, brain and lesion volumes on imaging, and serum biomarkers such as neurofilament light chain. Future studies should aim to include larger and more diverse cohorts, extend the follow-up duration, and incorporate imaging and biological markers to more accurately characterize the longitudinal relationship between MS progression and sleep quality.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par38">In conclusion, our study demonstrates that poor sleep quality is highly prevalent among PwMS and is significantly associated with reduced quality of life. Although sleep quality tended to remain stable over time, a considerable proportion of patients experienced further deterioration. The strong associations between poor sleep and neurological factors, particularly optic dysfunction and depression, underscore the need for personalized sleep management strategies.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_18693_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Habin Yun conceptualized and designed the study, analyzed data, wrote the main text and prepared figures and tables. Da Yeong Seo was responsible for data collection. Eun-Jae Lee provided critical revisions and contributed to the interpretation of results. All authors participated in manuscript drafting, reviewed the final version, and approved it for submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by grants from the National Research Foundation of Korea (NRF), funded by the Korean government (MSIT) (RS-2023-NR077202), the Asan Medical Center (2024IF0027), and the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea (HR21C0198).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study available from the corresponding author or the first author (Habin Yun, mail : habin0330@gmail.com) on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par39">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical considerations</title><p id="Par40">The study was conducted in compliance with the principles of the Declaration of Helsinki, and received approval from the Institutional Review Board/Ethics Committee of Asan Medical Center (No. 2018&#8201;&#8722;&#8201;0653).</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par41">All participants provided written informed consent.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhlmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multiple sclerosis progression: time for a new mechanism-driven framework</article-title><source>Lancet Neurol.</source><year>2023</year><volume>22</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00289-7</pub-id><pub-id pub-id-type="pmid">36410373</pub-id><pub-id pub-id-type="pmcid">PMC10463558</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. <italic toggle="yes">Lancet Neurol.</italic><bold>22</bold>, 78&#8211;88 (2023).<pub-id pub-id-type="pmid">36410373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00289-7</pub-id><pub-id pub-id-type="pmcid">PMC10463558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis Optica spectrum disorders versus multiple sclerosis</article-title><source>Sci. Rep.</source><year>2025</year><volume>15</volume><fpage>11326</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-95773-6</pub-id><pub-id pub-id-type="pmid">40175444</pub-id><pub-id pub-id-type="pmcid">PMC11965290</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Shin, W. et al. Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis Optica spectrum disorders versus multiple sclerosis. <italic toggle="yes">Sci. Rep.</italic><bold>15</bold>, 11326 (2025).<pub-id pub-id-type="pmid">40175444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-95773-6</pub-id><pub-id pub-id-type="pmcid">PMC11965290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soares-dos-Reis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Multiple sclerosis after the age of 50 years: a comparative analysis of late onset and adult onset</article-title><source>J. Clin. Neurol. (Seoul Korea)</source><year>2025</year><volume>21</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.3988/jcn.2024.0302</pub-id><pub-id pub-id-type="pmcid">PMC12056141</pub-id><pub-id pub-id-type="pmid">40308015</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Soares-dos-Reis, R. et al. Multiple sclerosis after the age of 50 years: a comparative analysis of late onset and adult onset. <italic toggle="yes">J. Clin. Neurol. (Seoul Korea)</italic>. <bold>21</bold>, 201 (2025).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3988/jcn.2024.0302</pub-id><pub-id pub-id-type="pmcid">PMC12056141</pub-id><pub-id pub-id-type="pmid">40308015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name><name name-style="western"><surname>Comabella</surname><given-names>M</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A</given-names></name></person-group><article-title>Multiple sclerosis: immunopathological heterogeneity and its implications</article-title><source>Eur. J. Immunol.</source><year>2022</year><volume>52</volume><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1002/eji.202149757</pub-id><pub-id pub-id-type="pmid">35476319</pub-id><pub-id pub-id-type="pmcid">PMC9324211</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Engelhardt, B., Comabella, M. &amp; Chan, A. Multiple sclerosis: immunopathological heterogeneity and its implications. <italic toggle="yes">Eur. J. Immunol.</italic><bold>52</bold>, 869&#8211;881 (2022).<pub-id pub-id-type="pmid">35476319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.202149757</pub-id><pub-id pub-id-type="pmcid">PMC9324211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multiple sclerosis</article-title><source>Nat. Rev. Dis. Primers</source><year>2018</year><volume>4</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0041-4</pub-id><pub-id pub-id-type="pmid">30410033</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Filippi, M. et al. Multiple sclerosis. <italic toggle="yes">Nat. Rev. Dis. Primers</italic>. <bold>4</bold>, 43 (2018).<pub-id pub-id-type="pmid">30410033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-018-0041-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Rui</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Sleep disorders in patients with multiple sclerosis in China</article-title><source>Sleep. Breath.</source><year>2017</year><volume>21</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1007/s11325-016-1416-y</pub-id><pub-id pub-id-type="pmid">27730345</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ma, S., Rui, X., Qi, P., Liu, G. &amp; Yang, J. Sleep disorders in patients with multiple sclerosis in China. <italic toggle="yes">Sleep. Breath.</italic><bold>21</bold>, 149&#8211;154 (2017).<pub-id pub-id-type="pmid">27730345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11325-016-1416-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laslett</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2022</year><volume>93</volume><fpage>1162</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2022-329227</pub-id><pub-id pub-id-type="pmid">35896381</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Laslett, L. L. et al. Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life. <italic toggle="yes">J. Neurol. Neurosurg. Psychiatry</italic>. <bold>93</bold>, 1162&#8211;1165 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-329227</pub-id><pub-id pub-id-type="pmid">35896381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veauthier</surname><given-names>C</given-names></name></person-group><article-title>Sleep disorders in multiple sclerosis. Review</article-title><source>Curr. Neurol. Neurosci. Rep.</source><year>2015</year><volume>15</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1007/s11910-015-0546-0</pub-id><pub-id pub-id-type="pmid">25773000</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Veauthier, C. Sleep disorders in multiple sclerosis. Review. <italic toggle="yes">Curr. Neurol. Neurosci. Rep.</italic><bold>15</bold>, 21 (2015).<pub-id pub-id-type="pmid">25773000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-015-0546-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braley</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>EA</given-names></name></person-group><article-title>Sleep disorders in multiple sclerosis</article-title><source>Curr. Neurol. Neurosci. Rep.</source><year>2016</year><volume>16</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1007/s11910-016-0649-2</pub-id><pub-id pub-id-type="pmid">27068547</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Braley, T. J. &amp; Boudreau, E. A. Sleep disorders in multiple sclerosis. <italic toggle="yes">Curr. Neurol. Neurosci. Rep.</italic><bold>16</bold>, 50 (2016).<pub-id pub-id-type="pmid">27068547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-016-0649-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouchaki</surname></name><name name-style="western"><surname>Ebrahim</surname></name></person-group><article-title>Sahar bayat, and Fatemeh Sadat asgarian. Sleep disorders in patients with multiple sclerosis</article-title><source>BMC Neurol.</source><year>2025</year><volume>25</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s12883-025-04247-9</pub-id><pub-id pub-id-type="pmid">40450208</pub-id><pub-id pub-id-type="pmcid">PMC12125843</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kouchaki &amp; Ebrahim Sahar bayat, and Fatemeh Sadat asgarian. Sleep disorders in patients with multiple sclerosis. <italic toggle="yes">BMC Neurol.</italic><bold>25</bold>, 1 (2025).<pub-id pub-id-type="pmid">40450208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-025-04247-9</pub-id><pub-id pub-id-type="pmcid">PMC12125843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Kallweit, Ulf, C. R. et al. Michael Linnebank, and Philipp O. Valko. Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant association? <italic toggle="yes">Multiple sclerosis international</italic> 1 (2013) (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/286581</pub-id><pub-id pub-id-type="pmcid">PMC3819751</pub-id><pub-id pub-id-type="pmid">24251039</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buratti</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sleep quality can influence the outcome of patients with multiple sclerosis</article-title><source>Sleep Med.</source><year>2019</year><volume>58</volume><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2019.02.020</pub-id><pub-id pub-id-type="pmid">31129524</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Buratti, L. et al. Sleep quality can influence the outcome of patients with multiple sclerosis. <italic toggle="yes">Sleep Med.</italic><bold>58</bold>, 56&#8211;60 (2019).<pub-id pub-id-type="pmid">31129524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleep.2019.02.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattarai</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis</article-title><source>Multiple Scler. Journal&#8211;Experimental Translational Clin.</source><year>2023</year><volume>9</volume><fpage>20552173231194352</fpage><pub-id pub-id-type="doi">10.1177/20552173231194352</pub-id><pub-id pub-id-type="pmcid">PMC10460472</pub-id><pub-id pub-id-type="pmid">37641617</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bhattarai, J. J. et al. Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis. <italic toggle="yes">Multiple Scler. Journal&#8211;Experimental Translational Clin.</italic><bold>9</bold>, 20552173231194352 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20552173231194352</pub-id><pub-id pub-id-type="pmcid">PMC10460472</pub-id><pub-id pub-id-type="pmid">37641617</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valentine</surname><given-names>TR</given-names></name><name name-style="western"><surname>Kratz</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kaplish</surname><given-names>N</given-names></name><name name-style="western"><surname>Chervin</surname><given-names>RD</given-names></name><name name-style="western"><surname>Braley</surname><given-names>TJ</given-names></name></person-group><article-title>Sleep-disordered breathing and neurocognitive function in multiple sclerosis: differential associations across cognitive domains</article-title><source>Multiple Scler. J.</source><year>2023</year><volume>29</volume><fpage>832</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1177/13524585231169465</pub-id><pub-id pub-id-type="pmid">37194432</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Valentine, T. R., Kratz, A. L., Kaplish, N., Chervin, R. D. &amp; Braley, T. J. Sleep-disordered breathing and neurocognitive function in multiple sclerosis: differential associations across cognitive domains. <italic toggle="yes">Multiple Scler. J.</italic><bold>29</bold>, 832&#8211;845 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585231169465</pub-id><pub-id pub-id-type="pmid">37194432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Alghanimy, A., Work, L. M. &amp; Holmes, W. M. The glymphatic system and multiple sclerosis: an evolving connection. <italic toggle="yes">Mult. Scler. Relat. Disord.</italic> 83, 105456 (2024). <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2024.105456</pub-id><pub-id pub-id-type="pmid">38266608</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria</article-title><source>Lancet Neurol.</source><year>2018</year><volume>17</volume><fpage>162</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30470-2</pub-id><pub-id pub-id-type="pmid">29275977</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <italic toggle="yes">Lancet Neurol.</italic><bold>17</bold>, 162&#8211;173 (2018).<pub-id pub-id-type="pmid">29275977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30470-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Longitudinal follow-up of serum biomarkers in patients with neuromyelitis Optica spectrum disorder</article-title><source>Multiple Scler. J.</source><year>2022</year><volume>28</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1177/13524585211024978</pub-id><pub-id pub-id-type="pmid">34212756</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kim, H. et al. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis Optica spectrum disorder. <italic toggle="yes">Multiple Scler. J.</italic><bold>28</bold>, 512&#8211;521 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585211024978</pub-id><pub-id pub-id-type="pmid">34212756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD</article-title><source>Neurology</source><year>2019</year><volume>93</volume><fpage>e1299</fpage><lpage>e1311</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000008160</pub-id><pub-id pub-id-type="pmid">31471502</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. <italic toggle="yes">Neurology</italic><bold>93</bold>, e1299&#8211;e1311 (2019).<pub-id pub-id-type="pmid">31471502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000008160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Blood neurofilament light chain as a biomarker of MS disease activity and treatment response</article-title><source>Neurology</source><year>2019</year><volume>92</volume><fpage>e1007</fpage><lpage>e1015</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007032</pub-id><pub-id pub-id-type="pmid">30737333</pub-id><pub-id pub-id-type="pmcid">PMC6442011</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. <italic toggle="yes">Neurology</italic><bold>92</bold>, e1007&#8211;e1015 (2019).<pub-id pub-id-type="pmid">30737333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007032</pub-id><pub-id pub-id-type="pmcid">PMC6442011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disanto</surname><given-names>G</given-names></name><etal/></person-group><article-title>Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis</article-title><source>Ann. Neurol.</source><year>2017</year><volume>81</volume><fpage>857</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1002/ana.24954</pub-id><pub-id pub-id-type="pmid">28512753</pub-id><pub-id pub-id-type="pmcid">PMC5519945</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. <italic toggle="yes">Ann. Neurol.</italic><bold>81</bold>, 857&#8211;870 (2017).<pub-id pub-id-type="pmid">28512753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24954</pub-id><pub-id pub-id-type="pmcid">PMC5519945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Ischemic stroke in patients with cancer: is it different from usual strokes?</article-title><source>Int. J. Stroke</source><year>2014</year><volume>9</volume><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/ijs.12124</pub-id><pub-id pub-id-type="pmid">23981525</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lee, E. J. et al. Ischemic stroke in patients with cancer: is it different from usual strokes? <italic toggle="yes">Int. J. Stroke</italic>. <bold>9</bold>, 406&#8211;412 (2014).<pub-id pub-id-type="pmid">23981525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijs.12124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Jerkovi&#263;, A. et al. Psychometric properties of the Pittsburgh Sleep Quality Index (PSQI) in patients with multiple sclerosis: factor structure, reliability, correlates, and discrimination. <italic toggle="yes">Journal of clinical medicine</italic> 11, (2022). (2037).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11072037</pub-id><pub-id pub-id-type="pmcid">PMC8999563</pub-id><pub-id pub-id-type="pmid">35407644</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Factors associated with poor sleep quality in the Korean general population: providing information from the Korean version of the Pittsburgh sleep quality index</article-title><source>J. Affect. Disord.</source><year>2020</year><volume>271</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2020.03.069</pub-id><pub-id pub-id-type="pmid">32312697</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lee, S. Y. et al. Factors associated with poor sleep quality in the Korean general population: providing information from the Korean version of the Pittsburgh sleep quality index. <italic toggle="yes">J. Affect. Disord.</italic><bold>271</bold>, 49&#8211;58 (2020).<pub-id pub-id-type="pmid">32312697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2020.03.069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Famodu, O. A. et al. Shortening of the pittsburgh sleep quality index survey using factor analysis. <italic toggle="yes">Sleep disorders</italic> 9643937 (2018). (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/9643937</pub-id><pub-id pub-id-type="pmcid">PMC5925150</pub-id><pub-id pub-id-type="pmid">29850262</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fried</surname><given-names>J</given-names></name><etal/></person-group><article-title>Changes in sleep quality following treatment for chronic rhinosinusitis: a systematic review and meta-analysis</article-title><source>Am. J. Rhinol. Allergy</source><year>2022</year><volume>36</volume><fpage>386</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1177/19458924211061442</pub-id><pub-id pub-id-type="pmid">34889643</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Fried, J. et al. Changes in sleep quality following treatment for chronic rhinosinusitis: a systematic review and meta-analysis. <italic toggle="yes">Am. J. Rhinol. Allergy</italic>. <bold>36</bold>, 386&#8211;396 (2022).<pub-id pub-id-type="pmid">34889643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19458924211061442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costandi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of long-term evoked compound action potential controlled closed-loop spinal cord stimulation on sleep quality in patients with chronic pain: an evoke randomized controlled trial study subanalysis</article-title><source>Neuromodulation: Technol. Neural Interface</source><year>2023</year><volume>26</volume><fpage>1030</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1016/j.neurom.2022.10.050</pub-id><pub-id pub-id-type="pmid">36437161</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Costandi, S. et al. Impact of long-term evoked compound action potential controlled closed-loop spinal cord stimulation on sleep quality in patients with chronic pain: an evoke randomized controlled trial study subanalysis. <italic toggle="yes">Neuromodulation: Technol. Neural Interface</italic>. <bold>26</bold>, 1030&#8211;1038 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurom.2022.10.050</pub-id><pub-id pub-id-type="pmid">36437161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Quality of life of patients with multiple sclerosis and neuromyelitis Optica spectrum disorders: cross-sectional and longitudinal analysis</article-title><source>Multiple Scler. Relat. Disorders</source><year>2022</year><volume>58</volume><fpage>103500</fpage><pub-id pub-id-type="doi">10.1016/j.msard.2022.103500</pub-id><pub-id pub-id-type="pmid">35032884</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kim, S. et al. Quality of life of patients with multiple sclerosis and neuromyelitis Optica spectrum disorders: cross-sectional and longitudinal analysis. <italic toggle="yes">Multiple Scler. Relat. Disorders</italic>. <bold>58</bold>, 103500 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2022.103500</pub-id><pub-id pub-id-type="pmid">35032884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><etal/></person-group><article-title>The EQ-5D-5L valuation study in Korea</article-title><source>Qual. Life Res.</source><year>2016</year><volume>25</volume><fpage>1845</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1007/s11136-015-1205-2</pub-id><pub-id pub-id-type="pmid">26961008</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kim, S. H. et al. The EQ-5D-5L valuation study in Korea. <italic toggle="yes">Qual. Life Res.</italic><bold>25</bold>, 1845&#8211;1852 (2016).<pub-id pub-id-type="pmid">26961008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11136-015-1205-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zurawski</surname><given-names>J</given-names></name><etal/></person-group><article-title>Time between expanded disability status scale (EDSS) scores</article-title><source>Multiple Scler. Relat. Disorders</source><year>2019</year><volume>30</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2019.02.007</pub-id><pub-id pub-id-type="pmid">30763908</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zurawski, J. et al. Time between expanded disability status scale (EDSS) scores. <italic toggle="yes">Multiple Scler. Relat. Disorders</italic>. <bold>30</bold>, 98&#8211;103 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2019.02.007</pub-id><pub-id pub-id-type="pmid">30763908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), 2019 version. (2019). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://icd.who.int/browse10/2019/en">https://icd.who.int/browse10/2019/en</ext-link></mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moradi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ebrahimian</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadigh-Eteghad</surname><given-names>S</given-names></name><name name-style="western"><surname>Talebi</surname><given-names>M</given-names></name><name name-style="western"><surname>Naseri</surname><given-names>A</given-names></name></person-group><article-title>Sleep quality in multiple sclerosis: A systematic review and meta-analysis based on Pittsburgh sleep quality index</article-title><source>Mult Scler. Relat. Disord</source><year>2025</year><volume>93</volume><fpage>106219</fpage><pub-id pub-id-type="doi">10.1016/j.msard.2024.106219</pub-id><pub-id pub-id-type="pmid">39674074</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Moradi, A., Ebrahimian, A., Sadigh-Eteghad, S., Talebi, M. &amp; Naseri, A. Sleep quality in multiple sclerosis: A systematic review and meta-analysis based on Pittsburgh sleep quality index. <italic toggle="yes">Mult Scler. Relat. Disord</italic>. <bold>93</bold>, 106219 (2025).<pub-id pub-id-type="pmid">39674074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2024.106219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Factors that influence sleep disturbance and the mediating effects of depression on sleep disturbance in patients with rheumatoid arthritis</article-title><source>Orthop. Nurs.</source><year>2022</year><volume>41</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/NOR.0000000000000880</pub-id><pub-id pub-id-type="pmid">36166609</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lee, S. et al. Factors that influence sleep disturbance and the mediating effects of depression on sleep disturbance in patients with rheumatoid arthritis. <italic toggle="yes">Orthop. Nurs.</italic><bold>41</bold>, 335&#8211;344 (2022).<pub-id pub-id-type="pmid">36166609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NOR.0000000000000880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Sleep quality in rheumatoid arthritis, and its association with disease activity in a Korean population</article-title><source>Korean J. Intern. Med.</source><year>2015</year><volume>30</volume><fpage>384</fpage><pub-id pub-id-type="doi">10.3904/kjim.2015.30.3.384</pub-id><pub-id pub-id-type="pmid">25995669</pub-id><pub-id pub-id-type="pmcid">PMC4438293</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Son, C. N. et al. Sleep quality in rheumatoid arthritis, and its association with disease activity in a Korean population. <italic toggle="yes">Korean J. Intern. Med.</italic><bold>30</bold>, 384 (2015).<pub-id pub-id-type="pmid">25995669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3904/kjim.2015.30.3.384</pub-id><pub-id pub-id-type="pmcid">PMC4438293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>N</given-names></name><name name-style="western"><surname>Hablitz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><article-title>The glymphatic system and pain</article-title><source>Med. Acupunct.</source><year>2020</year><volume>32</volume><fpage>373</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1089/acu.2020.1489</pub-id><pub-id pub-id-type="pmid">33362890</pub-id><pub-id pub-id-type="pmcid">PMC7755843</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Goldman, N., Hablitz, L. M., Mori, Y. &amp; Nedergaard, M. The glymphatic system and pain. <italic toggle="yes">Med. Acupunct.</italic><bold>32</bold>, 373&#8211;376 (2020).<pub-id pub-id-type="pmid">33362890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/acu.2020.1489</pub-id><pub-id pub-id-type="pmcid">PMC7755843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>S</given-names></name><name name-style="western"><surname>Djilas</surname><given-names>V</given-names></name><name name-style="western"><surname>Seidman</surname><given-names>LC</given-names></name><name name-style="western"><surname>Zeltzer</surname><given-names>LK</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>JC</given-names></name></person-group><article-title>Sleep quality, affect, pain, and disability in children with chronic pain: is affect a mediator or moderator?</article-title><source>J. Pain</source><year>2017</year><volume>18</volume><fpage>1087</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2017.04.007</pub-id><pub-id pub-id-type="pmid">28479208</pub-id><pub-id pub-id-type="pmcid">PMC5581256</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Evans, S., Djilas, V., Seidman, L. C., Zeltzer, L. K. &amp; Tsao, J. C. Sleep quality, affect, pain, and disability in children with chronic pain: is affect a mediator or moderator? <italic toggle="yes">J. Pain</italic>. <bold>18</bold>, 1087&#8211;1095 (2017).<pub-id pub-id-type="pmid">28479208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2017.04.007</pub-id><pub-id pub-id-type="pmcid">PMC5581256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>MB</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>PD</given-names></name></person-group><article-title>Sleep problems are associated with chronic pain over and above mutual associations with depression and catastrophizing</article-title><source>Clin. J. Pain</source><year>2016</year><volume>32</volume><fpage>792</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1097/AJP.0000000000000329</pub-id><pub-id pub-id-type="pmid">26710225</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Roberts, M. B. &amp; Drummond, P. D. Sleep problems are associated with chronic pain over and above mutual associations with depression and catastrophizing. <italic toggle="yes">Clin. J. Pain</italic>. <bold>32</bold>, 792&#8211;799 (2016).<pub-id pub-id-type="pmid">26710225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0000000000000329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferini-Strambi</surname><given-names>L</given-names></name></person-group><article-title>Neuropathic pain and sleep: a review</article-title><source>Pain Therapy</source><year>2017</year><volume>6</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s40122-017-0089-y</pub-id><pub-id pub-id-type="pmid">29178036</pub-id><pub-id pub-id-type="pmcid">PMC5701896</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Ferini-Strambi, L. Neuropathic pain and sleep: a review. <italic toggle="yes">Pain Therapy</italic>. <bold>6</bold>, 19&#8211;23 (2017).<pub-id pub-id-type="pmid">29178036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40122-017-0089-y</pub-id><pub-id pub-id-type="pmcid">PMC5701896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>SA</given-names></name></person-group><article-title>Glymphatic failure as a final common pathway to dementia</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Nedergaard, M. &amp; Goldman, S. A. Glymphatic failure as a final common pathway to dementia. <italic toggle="yes">Science</italic><bold>370</bold>, 50&#8211;56 (2020).<pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb8739</pub-id><pub-id pub-id-type="pmcid">PMC8186542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>H</given-names></name><etal/></person-group><article-title>Usefulness of the MFIS-K, FSS, and FACIT-F fatigue scales in Korean patients with MS, NMOSD, and MOGAD</article-title><source>J. Clin. Neurol.</source><year>2024</year><volume>20</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.3988/jcn.2023.0328</pub-id><pub-id pub-id-type="pmid">38951976</pub-id><pub-id pub-id-type="pmcid">PMC11220359</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ju, H. et al. Usefulness of the MFIS-K, FSS, and FACIT-F fatigue scales in Korean patients with MS, NMOSD, and MOGAD. <italic toggle="yes">J. Clin. Neurol.</italic><bold>20</bold>, 431&#8211;438 (2024).<pub-id pub-id-type="pmid">38951976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3988/jcn.2023.0328</pub-id><pub-id pub-id-type="pmcid">PMC11220359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotterba</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study</article-title><source>BMC Neurol.</source><year>2018</year><volume>18</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12883-018-1113-5</pub-id><pub-id pub-id-type="pmid">30143019</pub-id><pub-id pub-id-type="pmcid">PMC6107945</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kotterba, S. et al. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study. <italic toggle="yes">BMC Neurol.</italic><bold>18</bold>, 1&#8211;10 (2018).<pub-id pub-id-type="pmid">30143019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-018-1113-5</pub-id><pub-id pub-id-type="pmcid">PMC6107945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Panda, S. Circadian physiology of metabolism. Science 354, 1008&#8211;1015 42. Elhadd, K., et al. The characterisation of sleep and circadian rhythm in neuromyelitis optica. <italic toggle="yes">Medical Research Archives</italic> 9(2021). (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aah4967</pub-id><pub-id pub-id-type="pmcid">PMC7261592</pub-id><pub-id pub-id-type="pmid">27885007</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joo</surname><given-names>J</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S</given-names></name></person-group><article-title>Circadian rhythm disruption in the pathogenesis of optic neuritis associated with multiple sclerosis</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2024</year><volume>65</volume><fpage>90</fpage><lpage>90</lpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Joo, J., Shah, A., Yu, M. &amp; Rao, S. Circadian rhythm disruption in the pathogenesis of optic neuritis associated with multiple sclerosis. <italic toggle="yes">Investig. Ophthalmol. Vis. Sci.</italic><bold>65</bold>, 90&#8211;90 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>5609</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-32748-5</pub-id><pub-id pub-id-type="pmid">37019946</pub-id><pub-id pub-id-type="pmcid">PMC10076295</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kim, H. J. et al. Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. <italic toggle="yes">Sci. Rep.</italic><bold>13</bold>, 5609 (2023).<pub-id pub-id-type="pmid">37019946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-32748-5</pub-id><pub-id pub-id-type="pmcid">PMC10076295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veauthier</surname><given-names>C</given-names></name></person-group><article-title>Poor versus good sleepers in patients under treatment for sleep-related breathing disorders: better is not good enough</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2014</year><volume>131</volume><fpage>3</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S58970</pub-id><pub-id pub-id-type="pmcid">PMC3900331</pub-id><pub-id pub-id-type="pmid">24465130</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Veauthier, C. Poor versus good sleepers in patients under treatment for sleep-related breathing disorders: better is not good enough. <italic toggle="yes">Neuropsychiatr. Dis. Treat.</italic><bold>131</bold>, 3 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S58970</pub-id><pub-id pub-id-type="pmcid">PMC3900331</pub-id><pub-id pub-id-type="pmid">24465130</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinstein</surname><given-names>A</given-names></name><etal/></person-group><article-title>The link between multiple sclerosis and depression</article-title><source>Nat. Rev. Neurol.</source><year>2014</year><volume>10</volume><fpage>507</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.139</pub-id><pub-id pub-id-type="pmid">25112509</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Feinstein, A. et al. The link between multiple sclerosis and depression. <italic toggle="yes">Nat. Rev. Neurol.</italic><bold>10</bold>, 507&#8211;517 (2014).<pub-id pub-id-type="pmid">25112509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2014.139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buysse</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>CF</given-names></name><name name-style="western"><surname>Monk</surname><given-names>TH</given-names></name><name name-style="western"><surname>Berman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></name></person-group><article-title>The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research</article-title><source>Psychiatry Res.</source><year>1989</year><volume>28</volume><fpage>193</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(89)90047-4</pub-id><pub-id pub-id-type="pmid">2748771</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R. &amp; Kupfer, D. J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. <italic toggle="yes">Psychiatry Res.</italic><bold>28</bold>, 193&#8211;213 (1989).<pub-id pub-id-type="pmid">2748771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1781(89)90047-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagnew</surname><given-names>B</given-names></name><etal/></person-group><article-title>The association of comorbidities with sleep quality among Australians with multiple sclerosis: insights from the Australian multiple sclerosis longitudinal study</article-title><source>Multiple Scler. J.</source><year>2024</year><volume>30</volume><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1177/13524585241248278</pub-id><pub-id pub-id-type="pmcid">PMC11134972</pub-id><pub-id pub-id-type="pmid">38738517</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Dagnew, B. et al. The association of comorbidities with sleep quality among Australians with multiple sclerosis: insights from the Australian multiple sclerosis longitudinal study. <italic toggle="yes">Multiple Scler. J.</italic><bold>30</bold>, 877&#8211;887 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585241248278</pub-id><pub-id pub-id-type="pmcid">PMC11134972</pub-id><pub-id pub-id-type="pmid">38738517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veauthier</surname><given-names>C</given-names></name><name name-style="western"><surname>Gaede</surname><given-names>G</given-names></name><name name-style="western"><surname>Radbruch</surname><given-names>H</given-names></name><name name-style="western"><surname>Wernecke</surname><given-names>KD</given-names></name><name name-style="western"><surname>Paul</surname><given-names>F</given-names></name></person-group><article-title>Poor sleep in multiple sclerosis correlates with Beck depression inventory values, but not with polysomnographic data</article-title><source>Sleep. Disorders</source><year>2016</year><volume>2016</volume><issue>1</issue><fpage>8378423</fpage><pub-id pub-id-type="pmid">26885399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/8378423</pub-id><pub-id pub-id-type="pmcid">PMC4739473</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Veauthier, C., Gaede, G., Radbruch, H., Wernecke, K. D. &amp; Paul, F. Poor sleep in multiple sclerosis correlates with Beck depression inventory values, but not with polysomnographic data. <italic toggle="yes">Sleep. Disorders</italic>. <bold>2016</bold> (1), 8378423 (2016).<pub-id pub-id-type="pmid">26885399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/8378423</pub-id><pub-id pub-id-type="pmcid">PMC4739473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fatigue, depression, and pain in multiple sclerosis: how neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms</article-title><source>Mult Scler. J.</source><year>2020</year><volume>28</volume><fpage>1020</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1177/1352458520972279</pub-id><pub-id pub-id-type="pmcid">PMC9131410</pub-id><pub-id pub-id-type="pmid">33179588</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Heitmann, H. et al. Fatigue, depression, and pain in multiple sclerosis: how neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms. <italic toggle="yes">Mult Scler. J.</italic><bold>28</bold>, 1020&#8211;1027 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458520972279</pub-id><pub-id pub-id-type="pmcid">PMC9131410</pub-id><pub-id pub-id-type="pmid">33179588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#199;inar</surname><given-names>BP</given-names></name><name name-style="western"><surname>Yorgun</surname><given-names>YG</given-names></name></person-group><article-title>What we learned from the history of multiple sclerosis measurement: expanded disability status scale</article-title><source>Noro Psikiyatr Ars</source><year>2018</year><volume>55</volume><fpage>S69</fpage><lpage>s75</lpage><pub-id pub-id-type="pmid">30692861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.29399/npa.23343</pub-id><pub-id pub-id-type="pmcid">PMC6278618</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">&#199;inar, B. P. &amp; Yorgun, Y. G. What we learned from the history of multiple sclerosis measurement: expanded disability status scale. <italic toggle="yes">Noro Psikiyatr Ars</italic>. <bold>55</bold>, S69&#8211;s75 (2018).<pub-id pub-id-type="pmid">30692861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.29399/npa.23343</pub-id><pub-id pub-id-type="pmcid">PMC6278618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>F</given-names></name><etal/></person-group><article-title>High STOP-Bang score indicates a high probability of obstructive sleep Apnoea</article-title><source>Br. J. Anaesth.</source><year>2012</year><volume>108</volume><issue>5</issue><fpage>768</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1093/bja/aes022</pub-id><pub-id pub-id-type="pmid">22401881</pub-id><pub-id pub-id-type="pmcid">PMC3325050</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Chung, F. et al. High STOP-Bang score indicates a high probability of obstructive sleep Apnoea. <italic toggle="yes">Br. J. Anaesth.</italic><bold>108</bold> (5), 768&#8211;775 (2012).<pub-id pub-id-type="pmid">22401881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aes022</pub-id><pub-id pub-id-type="pmcid">PMC3325050</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bene&#353;</surname><given-names>H</given-names></name><name name-style="western"><surname>Kohnen</surname><given-names>R</given-names></name></person-group><article-title>Validation of an algorithm for the diagnosis of restless legs syndrome: the restless legs Syndrome-Diagnostic index (RLS-DI)</article-title><source>Sleep Med.</source><year>2009</year><volume>10</volume><issue>5</issue><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2008.06.006</pub-id><pub-id pub-id-type="pmid">18823819</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Bene&#353;, H. &amp; Kohnen, R. Validation of an algorithm for the diagnosis of restless legs syndrome: the restless legs Syndrome-Diagnostic index (RLS-DI). <italic toggle="yes">Sleep Med.</italic><bold>10</bold> (5), 515&#8211;523 (2009).<pub-id pub-id-type="pmid">18823819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleep.2008.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacco</surname><given-names>R</given-names></name><etal/></person-group><article-title>Psychometric properties and validity of Beck depression inventory II in multiple sclerosis</article-title><source>Eur. J. Neurol.</source><year>2016</year><volume>23</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1111/ene.12932</pub-id><pub-id pub-id-type="pmid">26782789</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Sacco, R. et al. Psychometric properties and validity of Beck depression inventory II in multiple sclerosis. <italic toggle="yes">Eur. J. Neurol.</italic><bold>23</bold>, 744&#8211;750 (2016).<pub-id pub-id-type="pmid">26782789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.12932</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>